The government of India has announced Phase 3 strategy of COVID-19 vaccination from May 1; everyone above the age of 18 to be eligible to get vaccine. Phase-I of the National Covid-19 Vaccination Strategy was launched on 16th January 2021, prioritizing protection for our protectors, our Health Care Workers (HCWs) and Front Line Workers (FLWs). As systems and processes stabilized, Phase-II was initiated from 1st March 2021, focusing on protecting our most vulnerable i.e. all people above 45 years of age, accounting for more than 80% Covid mortality in the country. The private sector was also roped in to augment capacity.
As per PM Modi’s directions, Government of India has proactively engaged and coordinated with stakeholders across the spectrum, from research institutes to national and international manufacturers, global regulators etc. The strength of India’s private sector vaccine manufacturing capability has been strategically empowered through unprecedented decisive steps, from facilitating public-private collaborative research, trials and product development, to targeted public grants and far-reaching governance reforms in India’s regulatory system.
In its Phase-III, the National Vaccine Strategy aims at liberalised vaccine pricing and scaling up of vaccine coverage. This would augment vaccine production as well as availability, incentivising vaccine manufacturers to rapidly ramp up their production as well as attract new vaccine manufacturers, domestic and international. It would also make pricing, procurement, eligibility and administration of vaccines open and flexible, allowing all stakeholders the flexibility to customise to local needs and dynamics.